keyword
MENU ▼
Read by QxMD icon Read
search

Anamorelin

keyword
https://www.readbyqxmd.com/read/30092794/the-management-strategies-of-cancer-associated-anorexia-a-critical-appraisal-of-systematic-reviews
#1
Fangyuan Zhang, Aomei Shen, Yinghui Jin, Wanmin Qiang
BACKGROUND: Cancer-related anorexia remains one of the most prevalent and troublesome clinical problems experienced by patients with cancer during and after therapy. To ensure high-quality care, systematic reviews (SRs) are seen as the best guide. Considering the methodology quality of SRs varies, we undertook a comprehensive overview, and critical appraisal of pertinent SRs. METHODS: Eight databases (between the inception of each database and September 1, 2017) were searched for SRs on the management of cancer-related anorexia...
August 9, 2018: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/29344250/prevention-of-body-weight-loss-and-sarcopenia-by-a-novel-selective-androgen-receptor-modulator-in-cancer-cachexia-models
#2
Megumi Morimoto, Katsuji Aikawa, Takahito Hara, Masuo Yamaoka
Cancer cachexia is a syndrome that impairs the quality of life and overall survival of patients, and thus the effectiveness of anticancer agents. There are no effective therapies for cancer cachexia due to the complexity of the syndrome, and insufficient knowledge of its pathogenesis results in difficulty establishing appropriate animal models. Previously, promising results have been obtained in clinical trials using novel agents including the ghrelin receptor agonist anamorelin, and the selective androgen receptor modulator (SARM) enobosarm to treat cachexia in patients with cancer...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29205286/anamorelin-ono-7643-for-the-treatment-of-patients-with-non-small-cell-lung-cancer-and-cachexia-results-from-a-randomized-double-blind-placebo-controlled-multicenter-study-of-japanese-patients-ono-7643-04
#3
Nobuyuki Katakami, Junji Uchino, Takuma Yokoyama, Tateaki Naito, Masashi Kondo, Kouzo Yamada, Hiromoto Kitajima, Kozo Yoshimori, Kazuhiro Sato, Hiroshi Saito, Keisuke Aoe, Tetsuya Tsuji, Yuichi Takiguchi, Koichi Takayama, Naoyuki Komura, Toru Takiguchi, Kenji Eguchi
BACKGROUND: Cachexia, described as weight loss (mainly in lean body mass [LBM]) and anorexia, is common in patients with advanced cancer. This study examined the efficacy and safety of anamorelin (ONO-7643), a novel selective ghrelin receptor agonist, in Japanese cancer patients with cachexia. METHODS: This double-blind clinical trial (ONO-7643-04) enrolled 174 patients with unresectable stage III/IV non-small cell lung cancer (NSCLC) and cachexia in Japan. Patients were randomized to daily oral anamorelin (100 mg) or a placebo for 12 weeks...
February 1, 2018: Cancer
https://www.readbyqxmd.com/read/29191597/anamorelin-for-advanced-non-small-cell-lung-cancer-with-cachexia-systematic-review-and-meta-analysis
#4
REVIEW
Kenichi Nishie, Shuhei Yamamoto, Chie Nagata, Tomonobu Koizumi, Masayuki Hanaoka
INTRODUCTION: Cancer anorexia-cachexia syndrome (CACS) is characterized by involuntary weight loss. CACS is commonly observed in advanced non-small-cell lung cancer (NSCLC), and it leads to a poor quality of life (QOL). No effective standard treatment exists for this condition. However, anamorelin has reportedly caused improvement in patients with several cancers. MATERIALS AND METHODS: We conducted a quantitative meta-analysis to explore the efficacy of anamorelin for treating CACS in patients with NSCLC...
October 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28957883/what-is-next-after-anamorelin
#5
REVIEW
Jose M Garcia
PURPOSE OF REVIEW: In spite of its relevance, treatments for the cancer anorexia and cachexia syndrome (CACS) are not available. One of the agents that recently reached phase III clinical trials is anamorelin. Its development, along with that of other agents for this indication, will be reviewed here, with a focus on the gaps in the current knowledge and future directions. RECENT FINDINGS: In spite of several targets showing promising results in early development, their difficulties obtaining regulatory approval underscore the need to reconsider the current strategies in drug development and the challenges in the field of CACS...
December 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28855797/oncology-update-anamorelin
#6
REVIEW
Eric Prommer
BACKGROUND: Cancer cachexia is a catabolic syndrome associated with uncontrolled muscle breakdown. There may be associated fat loss. Occurring in high frequency in advanced cancer, it is an indicator of poor prognosis. Besides weight loss, patients experience a cluster of symptoms including anorexia, early satiety, and weakness. The 3 stages of cachexia include stages of precachexia, cachexia, and refractory cachexia. Refractory cachexia is associated with active catabolism or the presence of factors that make active management of weight loss no longer possible...
2017: Palliative Care
https://www.readbyqxmd.com/read/28848326/anamorelin-hydrochloride-in-the-treatment-of-cancer-anorexia-cachexia-syndrome-design-development-and-potential-place-in-therapy
#7
REVIEW
Solomon A Graf, Jose M Garcia
Cancer anorexia-cachexia syndrome (CACS) is a complex and largely untreatable paraneoplastic complication common in advanced cancer. It is associated with profoundly deleterious effects on quality of life and survival. Since its discovery over a decade ago, anamorelin hydrochloride (anamorelin), a mimetic of the growth hormone secretagogue ghrelin, has shown considerable promise in ameliorating components of CACS when administered to patients with advanced cancer, including loss of lean body mass and reversal of anorexia...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28807233/overcoming-obstacles-in-the-design-of-cancer-anorexia-weight-loss-trials
#8
REVIEW
Jennifer G Le-Rademacher, Jeffrey Crawford, William J Evans, Aminah Jatoi
Most advanced cancer patients suffer loss of appetite (anorexia) and loss of weight. Despite the fact that cancer anorexia and weight loss are associated with a poor prognosis and detract from quality of life, no interventions have been demonstrated to palliate this syndrome in its entirety, particularly in patients with treatment-refractory malignancies. Recently, two registration trials - one with anamorelin and another with enobosarm - failed to reach their primary endpoints, thus raising questions. Were both these agents ineffective? Alternatively, did study design issues compromise the ability of these trials to identify effective agents? Thus, this review is timely insofar it serves as an introduction to study design, offers guidance on how to test promising agents for cancer anorexia/weight loss, and provides advice for overcoming trial design obstacles...
September 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28621564/the-emerging-role-of-anamorelin-hydrochloride-in-the-management-of-patients-with-cancer-anorexia-cachexia
#9
David C Currow, Richard Je Skipworth
Cancer cachexia affects many patients with advanced cancer. This multifactorial syndrome, which involves loss of muscle mass and body weight, profoundly affects patients' physical functioning and quality of life. Pharmacologic interventions that target weight loss and also improve patient-reported measures are required. Anamorelin hydrochloride is an oral ghrelin receptor agonist for the treatment of cancer anorexia-cachexia that stimulates release of growth hormone and insulin-like growth factor 1, and improves food intake and body weight...
August 2017: Future Oncology
https://www.readbyqxmd.com/read/28472437/romana-3-a-phase-3-safety-extension-study-of-anamorelin-in-advanced-non-small-cell-lung-cancer-nsclc-patients-with-cachexia
#10
D Currow, J S Temel, A Abernethy, J Milanowski, J Friend, K C Fearon
Background: Cancer anorexia-cachexia is a debilitating condition frequently observed in NSCLC patients, characterized by decreased body weight, reduced food intake, and impaired quality of life. Anamorelin, a novel selective ghrelin receptor agonist, has anabolic and appetite-enhancing activities. Patients and methods: ROMANA 3 was a safety extension study of two phase 3, double-blind studies that assessed safety and efficacy of anamorelin in advanced NSCLC patients with cachexia...
August 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28074289/anamorelin-for-cancer-anorexia-cachexia-syndrome-a-systematic-review-and-meta-analysis
#11
REVIEW
Yu Bai, Yunxia Hu, Yanhua Zhao, Xizhong Yu, Junwei Xu, Zhiyun Hua, Zhiqiang Zhao
PURPOSE: The aim of this study was to evaluate the therapeutic effects of Anamorelin on patients with cancer anorexia-cachexia syndrome (CACS) based on a meta-analysis of published randomized trials. METHODS: We searched PubMed, Embase, Medline, and the Cochrane Central Register of Controlled Trials databases. Data from each selected study were evaluated individually. All continuous outcomes were calculated by the mean difference or standardized mean difference with 95% confidence interval for each study...
May 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27382931/novel-therapeutic-options-for-cachexia-and-sarcopenia
#12
REVIEW
Alessio Molfino, Maria Ida Amabile, Filippo Rossi Fanelli, Maurizio Muscaritoli
INTRODUCTION: Cachexia and sarcopenia are conditions phenotypically characterized by muscle loss and represent a factor of poor prognosis, increasing patients' morbidity and mortality. Cachectic and sarcopenic patients often suffer from low quality of life, presenting lower muscle strength and appetite loss, which makes research on novel treatment strategies to ameliorate clinical response including patient's symptoms, the objective of scientific interest. AREAS COVERED: This article covers recent developments in the area of cachexia and sarcopenia treatment and therapeutic interventions, targeting central nervous system involvement, key inflammatory and muscle-specific metabolic pathways...
October 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27005463/anamorelin-ono-7643-in-japanese-patients-with-non-small-cell-lung-cancer-and-cachexia-results-of-a-randomized-phase-2-trial
#13
RANDOMIZED CONTROLLED TRIAL
Koichi Takayama, Nobuyuki Katakami, Takuma Yokoyama, Shinji Atagi, Kozo Yoshimori, Hiroshi Kagamu, Hiroshi Saito, Yuichi Takiguchi, Keisuke Aoe, Akira Koyama, Naoyuki Komura, Kenji Eguchi
PURPOSE: Cancer cachexia is characterized by decreased body weight (mainly lean body mass [LBM]) and negatively impacts quality of life (QOL) and prognosis. Anamorelin (ONO-7643) is a novel selective ghrelin receptor agonist under development for treating cancer cachexia. METHODS: In this double-blind, exploratory phase 2 trial, we examined the efficacy and safety of anamorelin in Japanese patients (n = 181) with non-small cell lung cancer (NSCLC) and cancer cachexia (≥5 % weight loss within the previous 6 months)...
August 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/26974316/clinical-results-in-cachexia-therapeutics
#14
REVIEW
Jeffrey Crawford
PURPOSE OF REVIEW: This article highlights recent developments in the area of cancer cachexia and therapeutic interventions. RECENT FINDINGS: Therapeutic interventions in cancer cachexia have been guided by clinical studies focused on the central role of muscle and the increased use of CT imaging to measure the impact of skeletal muscle loss on clinical outcomes. At the translational level, a number of different model systems have emphasized the importance of blockade of tumor-induced inflammation and its potential impact on reversing the cachexia phenotype, including FN14, a receptor in the TNF pathway, as well as the parathyroid hormone-related protein...
May 2016: Current Opinion in Clinical Nutrition and Metabolic Care
https://www.readbyqxmd.com/read/26906526/anamorelin-in-patients-with-non-small-cell-lung-cancer-and-cachexia-romana-1-and-romana-2-results-from-two-randomised-double-blind-phase-3-trials
#15
RANDOMIZED CONTROLLED TRIAL
Jennifer S Temel, Amy P Abernethy, David C Currow, John Friend, Elizabeth M Duus, Ying Yan, Kenneth C Fearon
BACKGROUND: Patients with advanced cancer frequently experience anorexia and cachexia, which are associated with reduced food intake, altered body composition, and decreased functionality. We assessed anamorelin, a novel ghrelin-receptor agonist, on cachexia in patients with advanced non-small-cell lung cancer and cachexia. METHODS: ROMANA 1 and ROMANA 2 were randomised, double-blind, placebo-controlled phase 3 trials done at 93 sites in 19 countries. Patients with inoperable stage III or IV non-small-cell lung cancer and cachexia (defined as ≥5% weight loss within 6 months or body-mass index <20 kg/m(2)) were randomly assigned 2:1 to anamorelin 100 mg orally once daily or placebo, with a computer-generated randomisation algorithm stratified by geographical region, cancer treatment status, and weight loss over the previous 6 months...
April 2016: Lancet Oncology
https://www.readbyqxmd.com/read/26675382/evidence-for-partial-pharmaceutical-reversal-of-the-cancer-anorexia-cachexia-syndrome-the-case-of-anamorelin
#16
Stefan D Anker, Andrew J S Coats, John E Morley
A major component of the cancer anorexia-cachexia syndrome is a decline in food intake. Up until now none of the drugs that improve appetite also improve skeletal muscle. Recent studies have suggested that the oral ghrelin-analog, anamorelin, increased food intake and muscle mass. Unfortunately, it does not increase muscle power. Its regulatory future is uncertain, although it has important clinical effects.
December 2015: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/26640742/an-open-label-clinical-trial-of-the-effects-of-age-and-gender-on-the-pharmacodynamics-pharmacokinetics-and-safety-of-the-ghrelin-receptor-agonist-anamorelin
#17
Philip T Leese, John M Trang, Robert A Blum, Eleanor de Groot
PURPOSE: To assess the effect of age and gender on the pharmacokinetics (PK) of the ghrelin receptor agonist anamorelin. METHODS: Three demographic cohorts of healthy subjects were enrolled in this single-center, open-label study. Subjects received a single oral dose (25 mg) of anamorelin HCl. Serial blood samples were collected over 24 hours to assess anamorelin PK and circulating growth hormone (GH) levels. Data were compared with a reference cohort. RESULTS: Anamorelin was rapidly absorbed in all cohorts; peak concentrations were observed 30-45 minutes and 2-4 hours post-dose, which declined biexponentially with mean terminal half-lives of 6-7 hours...
March 2015: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/26578461/simplifying-and-expanding-the-screening-for-peptides-2-kda-by-direct-urine-injection-liquid-chromatography-and-ion-mobility-mass-spectrometry
#18
Andreas Thomas, Christian Görgens, Sven Guddat, Detlef Thieme, Frank Dellanna, Wilhelm Schänzer, Mario Thevis
The analysis of low-molecular-mass peptides in doping controls has become a mandatory aspect in sports drug testing and, thus, the number of samples that has to be tested for these analytes has been steadily increasing. Several peptides <2 kDa with performance-enhancing properties are covered by the list of prohibited substances of the World Anti-Doping Agency including Desmopressin, LH-RH, Buserelin, Triptorelin, Leuprolide, GHRP-1, GHRP-2, GHRP-3, GHRP-4, GHRP-5,GHRP-6, Alexamorelin, Ipamorelin, Hexarelin, ARA-290, AOD-9604, TB-500 and Anamorelin...
January 2016: Journal of Separation Science
https://www.readbyqxmd.com/read/26435290/cancer-cachexia-one-step-ahead
#19
REVIEW
Fausto Meriggi
Cachexia is one of the most common manifestations in advanced cancer patients, but too often it remains under- recognized and under-treated. Starvation is not the same of cachexia. Cachexia is defined by "weight loss >5% over past 6 months in absence of simple starvation or the combination of ongoing weight loss>2% with BMI <20 or sarcopenia". The pathogenesis of cancer cachexia is not fully understood, but inflammation and an increased catabolic response to a number of cancer-related factors seem to represent the basis of any assumption...
2015: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/26386985/mechanisms-of-anorexia-cachexia-syndrome-and-rational-for-treatment-with-selective-ghrelin-receptor-agonist
#20
REVIEW
Angela Esposito, Carmen Criscitiello, Lucia Gelao, Gabriella Pravettoni, Marzia Locatelli, Ida Minchella, Maria Di Leo, Rita Liuzzi, Alessandra Milani, Mariangela Massaro, Giuseppe Curigliano
Cancer cachexia is a multi-organ, multifactorial and often irreversible syndrome affecting many patients with cancer. Cancer cachexia is invariably associated with weight loss, mainly from loss of skeletal muscle and body fat, conditioning a reduced quality of life due to asthenia, anorexia, anaemia and fatigue. Treatment options for treating cancer cachexia are limited. The approach is multimodal and may include: treatment of secondary gastrointestinal symptoms, nutritional treatments, drug, and non-drug treatments...
November 2015: Cancer Treatment Reviews
keyword
keyword
161617
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"